Business Context and Reporting Period
This Form 8-K was filed by Catalyst Biosciences, Inc. (not Gyre Therapeutics, Inc.) on July 22, 2021. The report covers a specific corporate event rather than a standard financial reporting period.
Key Financial Metrics
This filing is a Current Report regarding a clinical milestone and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The material event reported is the screening of the first patient in the Company's CFI-deficiency study for the CB 4332 program. CB 4332 is a wholly-owned, first-in-class, enhanced Complement Factor I (CFI) intended for prophylactic subcutaneous administration in individuals with CFI deficiency.
Guidance, Outlook, and Risks
The filing incorporates by reference a press release (Exhibit 99.1) detailing the clinical progress. No specific financial guidance, outlook, or discussion of risks and contingencies is included in the text of this 8-K summary.
Investor Verification Checklist
- Verify the registrant name is Catalyst Biosciences, Inc. (Ticker: CBIO), not Gyre Therapeutics.
- Confirm the status of the CB 4332 clinical trial via the referenced press release (Exhibit 99.1).
- Review the most recent 10-K or 10-Q for financial metrics, as this 8-K contains no financial data.